EUROCINE VACCINES AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.026 SEK | -14.47% |
|
-52.73% | -43.48% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 0.07 0.76 0.1 | Sales 2023 | 0 0.05 0.01 | Capitalization | 9.09M 98.29M 12.43M |
|---|---|---|---|---|---|
| Net income 2022 | -20M -216M -27.36M | Net income 2023 | -18M -195M -24.63M | EV / Sales 2022 | 119,226,800 x |
| Net cash position 2022 | 14.24M 154M 19.48M | Net cash position 2023 | 1.04M 11.28M 1.43M | EV / Sales 2023 | 1,608,986,800 x |
| P/E ratio 2022 |
-0.93
x | P/E ratio 2023 |
-0.41
x | Employees | 3 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 4.17% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -14.47% | ||
| 1 week | -52.73% | ||
| Current month | -24.42% | ||
| 1 month | +52.94% | ||
| 3 months | -17.72% | ||
| 6 months | -58.06% | ||
| Current year | -43.48% |
1 week
0.03
0.05
1 month
0.010.11
Current year
0.010.11
1 year
0.011.39
3 years
0.016.92
5 years
0.0127.40
10 years
0.011 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hans Arwidsson
CEO | Chief Executive Officer | 66 | 03-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 86 | 11-12-31 | |
Hans Arwidsson
CEO | Chief Executive Officer | 66 | 03-12-31 |
Pär Thuresson
BRD | Director/Board Member | 64 | 03-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 0.026 | -14.47% | 4,598,240 |
| 24-05-02 | 0.0304 | -11.63% | 6,628,450 |
| 24-04-30 | 0.0344 | +8.86% | 2,750,430 |
| 24-04-29 | 0.0316 | -42.55% | 11,574,236 |
End-of-day quote NORDIC GROWTH MARKET, May 02, 2024
More quotes
Eurocine Vaccines AB is a Sweden-based clinical-stage company, which develops nasal vaccines. The Company develops vaccines up to proof of concept (clinical phase I/II) and license to partners for further development and commercialization. Also, the Company offers license partners vaccine adjuvant technologies, which are a key element of the nasal vaccines, for development in various indications. For these purposes the Companyâs uses its clinically validated technology Endocine. In addition, the Companyâs primary project is the nasal quadrivalent influenza vaccine Immunos FLU that aims for children from six month. The Company cooperates with both academic researchers and contract businesses and owns all income generated in these collaborations.
Calendar
2024-05-21
- Q3 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -43.48% | 462K | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- EUCI Stock
